相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Population pharmacokinetics of rucaparib in patients with advanced ovarian cancer or other solid tumors
Michelle L. Green et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2022)
Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial
Rebecca Kristeleit et al.
LANCET ONCOLOGY (2022)
Rucaparib plus enzalutamide in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Pharmacokinetics (PK) and safety data from the phase Ib RAMP study
Arpit Rao et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Comparative Efficacy and Safety of PARP Inhibitors as Maintenance Therapy in Platinum Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis
Yangchun Xu et al.
FRONTIERS IN ONCOLOGY (2021)
Pharmacokinetics and safety of rucaparib in patients with advanced solid tumors and hepatic impairment
Nikolay Grechko et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2021)
Population exposure-efficacy and exposure-safety analyses for rucaparib in patients with recurrent ovarian carcinoma from Study 10 and ARIEL2
Gottfried E. Konecny et al.
GYNECOLOGIC ONCOLOGY (2021)
Differences in PARP Inhibitors for the Treatment of Ovarian Cancer: Mechanisms of Action, Pharmacology, Safety, and Efficacy
Giorgio Valabrega et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Comparison of the Efficacy and Safety of PARP Inhibitors as a Monotherapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis
Hongmei Wang et al.
FRONTIERS IN ONCOLOGY (2021)
A phase 1, open-label, drug-drug interaction study of rucaparib with rosuvastatin and oral contraceptives in patients with advanced solid tumors
Mingxiang Liao et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2021)
Acquired RAD51C Promoter Methylation Loss Causes PARP Inhibitor Resistance in High-Grade Serous Ovarian Carcinoma
Ksenija Nesic et al.
CANCER RESEARCH (2021)
Evaluation of absorption, distribution, metabolism, and excretion of [14C]-rucaparib, a poly(ADP-ribose) polymerase inhibitor, in patients with advanced solid tumors
Mingxiang Liao et al.
INVESTIGATIONAL NEW DRUGS (2020)
Discrepancy in calculated and measured glomerular filtration rates in patients treated with PARP inhibitors
Graziela Zibetti Dal Molin et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2020)
Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study
Wassim Abida et al.
CLINICAL CANCER RESEARCH (2020)
Evaluation of in vitro absorption, distribution, metabolism, and excretion and assessment of drug-drug interaction of rucaparib, an orally potent poly(ADP-ribose) polymerase inhibitor
Mingxiang Liao et al.
XENOBIOTICA (2020)
Rucaparib population pharmacokinetics (PPK) and exposure-response (ER) analyses in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) in TRITON2
S. Chowdhury et al.
ANNALS OF ONCOLOGY (2020)
Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration
Wassim Abida et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Evaluation of Drug-Drug Interactions of Rucaparib and CYP1A2, CYP2C9, CYP2C19, CYP3A, and P-gp Substrates in Patients With an Advanced Solid Tumor
Jim J. Xiao et al.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2019)
Exploring and comparing adverse events between PARP inhibitors
Christopher J. LaFargue et al.
LANCET ONCOLOGY (2019)
Intracranial evaluation of the in vivo pharmacokinetics, brain distribution, and efficacy of rucaparib in BRCA-mutant, triple-negative breast cancer
Minh Nguyen et al.
CANCER RESEARCH (2019)
Pharmacokinetic Study of Rucaparib in Patients With Advanced Solid Tumors
Geoffrey Shapiro et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2019)
PARP Inhibitors in Ovarian Cancer
Gloria Mittica et al.
RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY (2018)
Pharmacokinetics and clinical response to single agent rucaparib in a dialysis dependent patient with BRCA associated breast and recurrent ovarian cancer
Justin A. Harold et al.
GYNECOLOGIC ONCOLOGY REPORTS (2018)
Rucaparib in patients with relapsed, primary platinum-sensitive high-grade ovarian carcinoma with germline or somatic BRCA mutations: Integrated summary of efficacy and safety from the phase II study ARIEL2
G. E. Konecny et al.
GYNECOLOGIC ONCOLOGY (2017)
Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2
Amit M. Oza et al.
GYNECOLOGIC ONCOLOGY (2017)
Evaluation of Renal Transporter Inhibition Using Creatinine as a Substrate In Vitro to Assess the Clinical Risk of Elevated Serum Creatinine
Sumathy Mathialagan et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2017)
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
Robert L. Coleman et al.
LANCET (2017)
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial
Elizabeth M. Swisher et al.
LANCET ONCOLOGY (2017)
A Phase I-II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline BRCA1/2-Mutated Ovarian Carcinoma or Other Solid Tumors
Rebecca Kristeleit et al.
CLINICAL CANCER RESEARCH (2017)
In vitro and in vivo assessment of the mechanism of action of the PARP inhibitor rucaparib
Liliane Robillard et al.
CANCER RESEARCH (2017)
A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours
Richard H. Wilson et al.
BRITISH JOURNAL OF CANCER (2017)
Evaluation of rucaparib and companionydiagnostics in the PARP inhibitor landscape for recurrent ovarian cancer therapy
Zachary B. Jenner et al.
FUTURE ONCOLOGY (2016)
Two decades beyond BRCA1/2: Homologous recombination, hereditary cancer risk and a target for ovarian cancer therapy
Christine S. Walsh
GYNECOLOGIC ONCOLOGY (2015)
Poly (ADP-Ribose) Polymerase Inhibitors: Recent Advances and Future Development
Clare L. Scott et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Homologous-recombination-deficient tumours are dependent on Polθ-mediated repair
Raphael Ceccaldi et al.
NATURE (2015)
Liquid chromatography-tandem mass spectrometric assay for the PARP inhibitor rucaparib in plasma
Rolf W. Sparidans et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2014)
Therapeutic Potential of the Poly(ADP-ribose) Polymerase Inhibitor Rucaparib for the Treatment of Sporadic Human Ovarian Cancer
Maike Ihnen et al.
MOLECULAR CANCER THERAPEUTICS (2013)
The elephant and the blind men: making sense of PARP inhibitors in homologous recombination deficient tumor cells
Silvana B. De Lorenzo et al.
FRONTIERS IN ONCOLOGY (2013)
The role of PARP inhibitors in the treatment of gynecologic malignancies
Raquel E. Reinbolt et al.
FRONTIERS IN ONCOLOGY (2013)
Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors
Elisabet Wahlberg et al.
NATURE BIOTECHNOLOGY (2012)
Synthetic lethality: General principles, utility and detection using genetic screens in human cells
Sebastian M. B. Nijman
FEBS LETTERS (2011)
Therapeutic Potential of Poly(ADP-ribose) Polymerase Inhibitor AG014699 in Human Cancers With Mutated or Methylated BRCA1 or BRCA2
Yvette Drew et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2011)
The underlying mechanism for the PARP and BRCA synthetic lethality: Clearing up the misunderstandings
Thomas Helleday
MOLECULAR ONCOLOGY (2011)
PTEN Loss Compromises Homologous Recombination Repair in Astrocytes: Implications for Glioblastoma Therapy with Temozolomide or Poly(ADP-Ribose) Polymerase Inhibitors
Brian McEllin et al.
CANCER RESEARCH (2010)
ATM Deficiency Sensitizes Mantle Cell Lymphoma Cells to Poly(ADP-Ribose) Polymerase-1 Inhibitors
Chris T. Williamson et al.
MOLECULAR CANCER THERAPEUTICS (2010)
PARP inhibition: PARP1 and beyond
Michele Rouleau et al.
NATURE REVIEWS CANCER (2010)
Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors
Ana M. Mendes-Pereira et al.
EMBO MOLECULAR MEDICINE (2009)
Phase I Study of the Poly (ADP-Ribose) Polymerase Inhibitor, AG014699, in Combination with Temozolomide in Patients with Advanced Solid Tumors
Ruth Plummer et al.
CLINICAL CANCER RESEARCH (2008)
Challenges of characterizing proarrhythmic risk due to QTc prolongation induced by nonadjuvant anticancer agents
Nenad Sarapa et al.
EXPERT OPINION ON DRUG SAFETY (2008)
A synthetic lethal therapeutic approach: Poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair
Alan Ashworth
JOURNAL OF CLINICAL ONCOLOGY (2008)
Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial
Huw D. Thomas et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Poly(ADP-ribose):: novel functions for an old molecule
Valerie Schreiber et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2006)
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
HE Bryant et al.
NATURE (2005)
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
H Farmer et al.
NATURE (2005)
Combined phenotypic assessment of cytochrome P450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase-2, and xanthine oxidase activities with the Cooperstown 5+1 cocktail
S Chainuvati et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2003)
Cancer susceptibility and the functions of BRCA1 and BRCA2
AR Venkitaraman
CELL (2002)
BRCA2 is required for homology-directed repair of chromosomal breaks
ME Moynahan et al.
MOLECULAR CELL (2001)
分享论文
